Ⓐ
PeptiBrief
Cardiovascular and Fibrosis

Relaxin family peptide receptor signalling

Activation of relaxin family peptide receptor 1 by relaxin-derived agonists.

Biological pathway

RXFP1 signalling engages ERK, nitric oxide and matrix-remodelling pathways; biased agonists may favour selected downstream effects.

Evidence summary

B7-33 has substantial preclinical antifibrotic and cardioprotective evidence but no established human therapeutic efficacy.

Limitations

Most evidence is animal or cellular, and biased signalling may differ by tissue and dose.

Peptides linked to this mechanism

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.